Manufacturing disruption or facility failure
Products are biologic therapies requiring controlled in-house production and supply continuity.
- Scope
- MACI and Epicel manufacturing in Massachusetts
- Materiality
- high
Vericel Corp
Vericel Corp is a U.S.-based biopharmaceutical company focused on advanced therapies for cartilage repair and severe burn care. Its commercial portfolio includes MACI for knee cartilage defects, Epicel for severe burns, and NexoBrid for burn eschar removal in North America through a license and supply arrangement.
8,2 %
74,4 %
6,0 %
+16,5 %
5.03
4.68
| % | |
|---|---|
| MACI | 75% Autologous cell therapy for repair of symptomatic knee cartilage defects. |
| Epicel | 15% Cultured epidermal autograft used for patients with severe burns. |
| NexoBrid | 5% Specialty biologic for enzymatic removal of burn eschar in burn care. |
| MACI Arthro and related instruments | 5% Arthroscopic delivery tools and accessories used with MACI implants. |
Vericel sells primarily to hospitals, specialty pharmacies, burn centers, and surgeons that treat patients with...
- Orthopedic surgeons and sports medicine centersprimary
Buy and implant MACI for symptomatic knee cartilage defects, especially higher-volume arthroscopic surgeons.
- Hospitals and specialty pharmaciesprimary
Dispense MACI under payer authorization and manage billing/collection for patient-specific use.
- Burn centers and hospital burn unitsprimary
Use Epicel and NexoBrid for severe burn treatment and eschar removal.
- Specialty distributorssecondary
Purchase NexoBrid and resell it to hospitals and burn centers.
- Military and institutional facilitiessecondary
Buy MACI under contracted arrangements for treatment at military facilities.
Vericel’s operations are concentrated in the United States, where it manufactures, markets, and sells its products...
- •All operations are located in the United States
- •100% of revenue is derived from domestic sales
- •Manufacturing is centered in Massachusetts
- •Commercial activity is focused on U.S. hospitals, burn centers, and surgeons
Vericel’s strategy centers on expanding adoption of its commercial therapies, especially MACI, while broadening surgeon...
01
Expand MACI surgeon adoption and procedure volumeshort-term
MACI is the core commercial product and depends on surgeon training and procedural penetration.
02
Build burn care franchise around Epicel and NexoBridmedium-term
Burn care provides a second specialty channel with focused institutional customers.
03
Increase manufacturing capacity and operational resiliencemedium-term
Cell therapy products require reliable in-house production and validated facilities.
Vericel faces concentration risk in a small number of specialty products, with demand tied to surgeon adoption,...
Quarterly and annual revenue volatility
Sales depend on procedure timing, seasonal patterns, and burn-care demand.
- Scope
- MACI, Epicel, NexoBrid
- Materiality
- high
Payer coverage and reimbursement risk
MACI shipments require prior authorization and reimbursement can vary by payer.
- Scope
- MACI
- Materiality
- high
Intellectual property and license dependence
Exclusive commercialization rights for NexoBrid depend on compliance with MediWound agreements.
- Scope
- NexoBrid
- Materiality
- high
Commercial adoption risk for NexoBrid
The product must gain acceptance in a specialized burn-care market to scale meaningfully.
- Scope
- North America commercialization rights
- Materiality
- medium
Competition from alternative cartilage and burn treatments
Established medical device and biologics companies compete in regenerative medicine and burn care.
- Scope
- MACI and Epicel
- Materiality
- medium
ASC 606 revenue recognition for MACI
Patient-specific reimbursement and denial rates affect reported sales
Contractual allowances and credit loss estimates
Can materially change net product revenue and receivables
Lease accounting for Massachusetts facilities
Affects operating expenses and balance sheet obligations
Valuation allowance on deferred tax assets
Can significantly affect tax expense and net income
: 29.4.2026